08th November 2018
Horizon Discovery Group plc
Cambridge, UK, 8 November 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global leader in the application of gene editing and gene modulation technologies, today announces the appointment of Margarita Krivitski as Non-Executive Director, with immediate effect.
Ms. Krivitski is a Vice President at ValueAct Capital Management, L.P. (“ValueAct Capital”), a San Francisco based investment firm. Prior to joining ValueAct Capital in September 2015, Ms. Krivitski worked at TPG Capital in the North American Buyout Group, focusing on investments across the healthcare industry. Prior to TPG Capital, Ms. Krivitski worked as an investment banker at Goldman Sachs in New York. She received a B.A. in Applied Mathematics from Harvard University.
ValueAct Capital is a key shareholder in Horizon, currently holding 13.3%. ValueAct has invested in Horizon Discovery through the ValueAct Spring Fund, a fund focused on making long term, concentrated investments in companies that are responsibly and creatively addressing environmental and social problems.
“I am pleased to welcome Margarita Krivitski to the Board of Horizon Discovery. We have engaged closely with ValueAct Capital and Margarita over recent months and are excited that they share our long term vision for growth and value creation. We look forward to Margarita’s participation as we execute our recently announced five-year strategic plan.”
Dr Ian GilhamNon-Executive Chairman of Horizon Discovery
“I have been deeply impressed by Horizon’s long-standing expertise in gene editing and the value that their products and services bring to customers, helping them advance scientific knowledge and discover novel therapeutics. I look forward to working closely with the Board and management team as they execute their strategic plan and drive long term value creation for all stakeholders.”
Margarita Krivitskiincoming Non-Executive Director at Horizon Discovery
Save as disclosed below, Horizon confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Margarita Krivitski's appointment.
Ms Margarita Krivitski is aged 29 and was formerly known as Margarita Krivitskaya.
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker HZD